Company Overview and News
Brookfield Infrastructure Partners L.P. (BIP - Free Report) is engaged in utility, transport, energy, and communications infrastructure businesses. The Zacks Consensus Estimate for its current year earnings has been revised 2.2% downward over the last 60 days.
EEFT BIP SND POWI FFIN
This is not a sign of weakness for frac sand players. On the contrary, it points to the flexibility that HCLP has with its supply chain to navigate temporary slowdowns.
2018-09-05 investorplace - 4
Whether you’re a newbie who just watched The Wolf of Wall Street or you’re a seasoned trader whose previous fliers on penny stocks have burned one too many holes in your pocket, the story is the same — stay away from penny stocks.
DLPN LWAY SBUX NFLX SND SLCA TYHT FOXA MCD DIS JVA
2018-08-18 seekingalpha - 2
Today's Idea Guide looks at a few ideas on companies whose futures seem to be pointed in one direction, to see if the market is right or just overreacting.
HBANN HBANO FIT HBANP LUB GOLF MANU HBAN GPRO ZNGA DRYS VALU AAPL DCIX KHC SND
Good day and welcome to the Smart Sand Second Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
2018-08-09 zacks - 1
Jounce Therapeutics, Inc. (JNCE - Free Report) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.
JNCE HCCDZ HCHC GWRS UCTI SND RLH UCTT
Cable One (CABO - Free Report) came out with quarterly earnings of $7.65 per share, missing the Zacks Consensus Estimate of $7.97 per share. This compares to earnings of $4.97 per share a year ago. These figures are adjusted for non-recurring items.
CABO HCCDZ HCHC GWRS UCTI SND RLH UCTT
Nomad Foods (NOMD - Free Report) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.
HCCDZ HCHC GWRS UCTI NOMD SND RLH UCTT
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to SND / Smart Sand, Inc. on message board site Silicon Investor.
as of ET